COLL · Collegium Pharmaceutical, Inc.

The nomination of Michael Donovan and retirement of Dr. John Fallon represent a planned evolution of Collegium Pharmaceutical’s Board composition. Donovan’s deep financial and life sciences background—spanning over three decades at EY, including leadership roles in biotechnology audit and advisory services—adds specialized oversight capability relevant to the Company’s development-stage pharmaceutical operations and capital markets activity. His CPA credential and hands-on experience with IPOs, financings, and M&A align with governance needs for a company navigating commercialization and potential strategic transactions. Dr. Fallon’s departure marks the end of a decade-long tenure beginning in 2016; his service included contributions during key phases of the Company’s growth, though the filing explicitly states his retirement is voluntary and aligned with ongoing board succession planning—not driven by performance or governance concerns. While director transitions are routine, this change introduces new financial rigor to the Board while maintaining continuity through the upcoming Annual Meeting, where shareholders will vote on Donovan’s election and formally conclude Fallon’s service.